Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
Hepatoprotective activity of lycopene in experimental paracetamol-induced liver injury in rats
Actividad hepatoprotectora del licopeno en la lesión hepática experimental inducida por paracetamol en ratas
Atividade hepatoprotetora do licopeno na lesão hepática experimental induzida por paracetamol em ratos
DOI:
https://doi.org/10.15446/rcciquifa.v51n3.107549Palabras clave:
Lycopene, paracetamol, ALT, AST (en)Licopeno, paracetamol, ALT, AST (es)
Licopeno, paracetamol, ALT, AST (pt)
Descargas
Aim: To evaluate the hepatoprotective effects of lycopene pretreatment in paracetamol-induced liver damage (PILD). Methods: Wistar rats were administered oral lycopene (4 mg/kg/day) by gastric lavage for 8 days. Subsequently, 3 g/kg paracetamol was administered on day 8. After 24 and 72 h, animals were euthanized, and intracardiac blood samples were collected to measure levels of aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase, and alkaline phosphatase (ALP). In addition, the liver was harvested for histological analyses. Results: Negative and positive control groups (treated with saline or paracetamol on day 8, respectively) were compared with lycopene- and lycopene-paracetamol-treated (lycopene+paracetamol on day 8) groups. Notably, we observed that 24 h after PILD, lycopene treatment significantly reduced serum transaminase (ALT/AST) levels when compared with those in the saline-treated group. Conclusion: Lycopene improved liver recovery following PILD. Although lycopene exhibits antioxidant action and has been indicated for liver diseases, its use must be cautiously undertaken, especially considering the liver patholog y involved, as results may vary for each underlying factor.
Objetivo: avaliar os efeitos hepatoprotetores do pré-tratamento com licopeno no dano hepático induzido por paracetamol (PILD). Metodologia: ratos Wistar receberam licopeno oral (4 mg/kg/dia) por lavagem gástrica por 8 dias. Posteriormente, 3 g/kg de paracetamol foi administrado no dia 8. Após 24 e 72 h, os animais foram eutanasiados e amostras de sangue intracardíaco foram coletadas para medir os níveis de aspartato aminotransferase (AST), alanina transaminase (ALT), gama-glutamil transferase, e fosfatase alcalina (ALP). Além disso, o fígado foi colhido para análises histológicas. Resultados: os grupos de controle negativo e positivo (tratados com solução salina ou paracetamol no dia 8, respectivamente) foram comparados com os grupos tratados com licopeno e licopeno-paracetamol (licopeno+paracetamol no dia 8). Notavelmente, observamos que 24 h após PILD, o tratamento com licopeno reduziu significativamente os níveis séricos de transaminase (ALT/AST) quando comparados com os do grupo tratado com solução salina. Conclusão: o licopeno melhorou a recuperação do fígado após PILD. Embora o licopeno exiba ação antioxidante e tenha sido indicado para doenças hepáticas, seu uso deve ser realizado com cautela, principalmente considerando a patologia hepática envolvida, pois os resultados podem variar para cada fator subjacente.
Objetivo: avaliar os efeitos hepatoprotetores do pré-tratamento com licopeno no dano hepático induzido por paracetamol (PILD). Metodologia: ratos Wistar receberam licopeno oral (4 mg/kg/dia) por lavagem gástrica por 8 dias. Posteriormente, 3 g/kg de paracetamol foi administrado no dia 8. Após 24 e 72 h, os animais foram eutanasiados e amostras de sangue intracardíaco foram coletadas para medir os níveis de aspartato aminotransferase (AST), alanina transaminase (ALT), gama-glutamil transferase, e fosfatase alcalina (ALP). Além disso, o fígado foi colhido para análises histológicas. Resultados: os grupos de controle negativo e positivo (tratados com solução salina ou paracetamol no dia 8, respectivamente) foram comparados com os grupos tratados com licopeno e licopeno-paracetamol (licopeno+paracetamol no dia 8). Notavelmente, observamos que 24 h após PILD, o tratamento com licopeno reduziu significativamente os níveis séricos de transaminase (ALT/AST) quando comparados com os do grupo tratado com solução salina. Conclusão: o licopeno melhorou a recuperação do fígado após PILD. Embora o licopeno exiba ação antioxidante e tenha sido indicado para doenças hepáticas, seu uso deve ser realizado com cautela, principalmente considerando a patologia hepática envolvida, pois os resultados podem variar para cada fator subjacente.
Referencias
A. Giancotti, M. Monti, L. Nevi, S. Safarikia, V. D’Ambrosio, R. Brunelli, C. Pajno, S. Corno, V. Di Donato, A. Musella, M.F. Chiappetta, D. Bosco, P.B. Panici, D. Alvaro, V. Cardinale, Functions and the emerging role of the foetal liver into regenerative medicine, Cells, 8(8), 914 (2019).
J.L. Boyer, C.J. Soroka, Bile formation and secretion: An update, J. Hepatol., 75(1), 190-201 (2021).
C.C. Bell, D.F.G. Hendriks, S.M.L. Moro, E. Ellis, J. Walsh, A. Renblom, L.F. Puigvert, A.C.A. Dankers, F. Jacobs, J. Snoeys, R.L. Sison-Young, R.E. Jenkins, Å. Nordling, S. Mkrtchian, B.K. Park, N.R. Kitteringham, C.E.P. Goldring, V.M. Lauschke, M. Ingelman-Sundberg,Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease, Sci. Rep., 6, 25187 (2016).
J.H. Kim, M. Wang, J. Lee, H.J. Park, C. Han, H.S. Hong, J.S. Kim, G.H. An, K. Park, H.K. Park, S.F. Zhu, X.B. Sun, J.H, Kim, D.H. Woo, Prediction of hepatotoxicity for drugs using human pluripotent stem cell-derived hepatocytes, Cell. Biol. Toxicol., 34, 51-64 (2018).
L.C. Matos, B. Martins, Hepatites tóxicas: revisão da literatura, Medicina Interna, 12(4), 239-258 (2005).
N.M.B.L. Prado, G.C. Messias, G.O.S. Junior, V.S. Nunes, M.I. Schinonni, R. Paraná, Prospective monitoring of drug use: drug-induced liver injury in a primary healthcare center, Arq. Gastroenterol., 56(4), 390-393 (2019).
K. Neil, Biochemical and cellular mechanisms of toxic liver injury, Sem. Liver Dis., 22(2),137-44 (2002).
M. Nita, A. Grzybowski, The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults, Oxid. Med. Cell. Longev., 2016, 3164734, (2016).
S.A. Monteiro e Silva, B. Michniak-Kohn, G.R. Leonardi, An overview about oxidation in clinical practice of skin aging, An. Bras. Dermatol., 92(3), 367-374 (2017).
C.A. Juan, J.M. Pérez de la Lastra, F.J. Plou, E. Pérez-Lebeña, The chemistry of reactive oxygen species (ROS) revisited: Outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies, Int. J. Mol. Sci., 22(9), 4642, (2021).
T.L. Litovitz, W. Klein-Schwartz, S. White, D.J. Cobaugh, J. Youniss, A. Drab, B.E. Benson, 1999 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System, The American Journal of Emergency Medicine, 18(5), 517-574 (2000).
K. Brune, B. Renner, G. Tiegs, Acetaminophen/paracetamol: A history of errors, failures and false decisions, Eur. J. Pain, 19(7), 953-965 (2015).
L. Rotundo, N. Pyrsopoulos, Liver injury induced by paracetamol and challenges associated with intentional and unintentional use, World J. Hepatol., 12(4), 125-136 (2020).
N.M.P. Maideen, Drug Interactions of Acetaminophen (Paracetamol) involving CYP and UGT Enzymes, Eur. J. Med., 7(1), 30-34 (2019).
M. Vairetti, L.G. Di Pasqua, M. Cagna, P. Richelmi, A. Ferrigno, C. Berardo, Changes in glutathione content in liver diseases: An Update, Antioxidants, 10(3), 364 (2021).
A.B. Reid, R. Kurten, S. McCullough, R. Brock, J. Hinson, Mechanisms of acetaminophen-induced hepatotoxicity: Role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes, J. Pharmacol. Exp. Th e r., 312(2), 509-516 (2005).
J.T. Hancock, Oxygen is instrumental for biological signaling : An overview, Oxygen, 1(1), 3-15, (2021).
P.P. Barros, G.H. da Silva, G.M.S. Gonçalves, J.C. Oliveira, L.G. Pagnan, L. Arcoe-Flexa, Hepatoprotective effect of quercetin pretreatment against paracetamol-induced liver damage and partial hepatectomy in rats, Braz. Arch. Biol. Technol., 60, e17160138, (2017).
H.S. Black, F. Boehm, R. Edge, T.G. Truscott, The benefits and risks of certain dietary carotenoids that exhibit both anti- and pro-oxidative mechanisms: A comprehensive review, Antioxidants (Basel), 9(3), 264 (2020).
A. Pérez-Gálvez, I. Viera, M. Roca, Carotenoids and chlorophylls as antioxidants, Antioxidants (Basel), 9(6), 505 (2020).
R.C. Mordi, O.T. Ademosun, C.O. Ajanaku, I.O. Olanrewaju, J.C. Walton, Free radical mediated oxidative degradation of carotenes and xanthophylls, Molecules, 25(5), 1038 (2020).
K. Erbakan, A. Doğanoğlu, O. Erbaş, Effects of lycopene on neurodegenerative diseases, Journal of Experimental and Basic Medical Sciences, 2(1), 50-61 (2021).
J.P. Islamian, H. Mehrali, Lycopene as a carotenoid provides radioprotectant and antioxidant effects by quenching radiation-induced free radical singlet oxygen: An overview, Cell J., 16(4), 386–391 (2015).
M. Mirahmadi, S. Azimi-Hashemi, E. Saburi, H. Kamali, M. Pishbin, F. Hadizadeh, Potential inhibitory effect of lycopene on prostate cancer, Biomed. Pharmacother., 129, 110459 (2020).
F. Gholami, J. Antonio, C. Evans, K. Cheraghi, L. Rahmani, F. Amirnezhad, Tomato powder is more effective than lycopene to alleviate exercise-induced lipid peroxidation in well-trained male athletes: randomized, double-blinded cross-over study, J. Int. Soc. Sports Nutr., 18(17), 17 (2021).
P.P. Barros, G.M.S. Gonçalves, G.H. da Silva, M.C.V.D. Bastos, L.N. Ramos, M.M. Fernandes, Lycopene and resveratrol pretreatment did not interfere with the liver of hepatectomized rats, Acta Cir. Bras., 32(3), 194-202 (2017).
P.J. Korytko, K.A. Rodvold, J.A. Crowell, M. Stacewicz-Sapuntzakis, V. Diwadkar-Navsariwala, P.E. Bowen, W. Schalch, B. S. Levine, Pharmacokinetics and tissue distribution of orally administered lycopene in male dogs, J. Nutr., 133(9), 2788-2792 (2003).
A.A. Oyagbemi, A.A. Odetola, Hepatoprotective effects of ethanolic extract of Cnidoscolus aconitifolius on paracetamol-induced hepatic damage in rats, Pak. J. Biol. Sci., 13(4), 164-169 (2010).
I.H. Bahcecioglu, N. Kuzu, K. Metin, I.H. Ozercan, B. Ustundag, K. Sahin, O. Kucuk, Lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet, lycopene prevents development of steatohepatitis in experimental nonalcoholic steatohepatitis model induced by high-fat diet, Vet. Med. Int., 2010, 262179, (2010).
A.A. Dantas, C.R. Ambiel, R.K.N. Cuman, S. Baroni, C.A. Bersani-Amado, Valores de referência de alguns parâmetros fisiológicos de ratos do Biotério Central da Universidade Estadual de Maringá, Estado do Paraná, Acta Sci. Health Sci., 28(2), 165-170 (2006).
M. Sharifi-Rad, N.V.A. Kumar, P. Zucca, E.M. Varoni, L. Dini, E. Panzarini, J. Rajkovic, P.V.T. Fokou, E. Azzini, I. Peluso, A.P. Mishra, M. Nigam, Y.E. Rayess, M.E. Beyrouthy, L. Polito, M. Iriti, N. Martins, M. Martorell, A.O. Docea, W.N. Setzer, D. Calina, W.C. Cho, J. Sharifi-Rad, Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiolog y of chronic diseases, Front. Physiol., 11(694), 694 (2020).
K.S. Shivashangari, V. Ravikumar, R. Vinodhkumar, S.A.A. Sheriff, T. Devaki, Hepatoprotective potential of lycopene on d-galactosamine/lipopolysaccharide induced hepatitis in Rats, Pharmacolog yonline, 2, 151-170 (2006).
A. Ramachandran, R.G.J. Visschers, L. Duan, J.Y. Akakpo, H. Jaeschke, Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives, J. Clin. Transl. Res., 4(1), 75-100 (2018).
E. Giannini, D. Risso, F. Botta, B. Chiarbonello, A. Fasoli, F. Malfatti, P. Romagnoli, E. Testa, P. Ceppa, R. Testa, Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease, Arch. Intern. Med., 163(2), 218-224 (2003).
H. Kang, S. Koppula, Hepatoprotective effect of Houttuynia cordata Thunb extract against carbon tetrachloride-induced hepatic damage in mice, Indian J. Pharm. Sci., 76(4), 267-273 (2014).
A.P. Amang, E. Kodji, C. Mezui, M.P. Baane, G.T. Siwe, T.M. Kuissu, J. Emakoua, P.V. Tan, Hepatoprotective effects of aqueous extract of Opilia celtidifolia(Opiliaceae) leaves against ethanol-induced liver damage in rats, Evidence-Based Complementary Altern. Med., 2020, 6297475, (2020).
D. Lowe, T. Sanvictores, S. John, Alkaline phosphatase, StatPearls Treasure Island (FL): StatPearls Publishing, 2022, URL: https://www.ncbi.nlm.nih.gov/books/NBK459201/#_NBK459201_pubdet_, accessed October, 2021.
M. Amjad, S. Hussain, A.R. Khan, Development and validation of HPLC assay of lycopene in different matrices, World Journal of Applied Chemistry, 5(2), 26-33 (2020).
J. Arballo, J. Amengual, J.W. Erdman Jr., Lycopene: A critical review of digestion, absorption, metabolism, and excretion, Antioxidants (Basel), 10(3), 342 (2021).
N. Hedayati, M.B. Naeini, A. Nezami, H. Hosseinzadeh, A.W. Hayes, S. Hosseini, M. Imenshahidi, G. Karimi, Protective effect of lycopene against chemical and natural toxins: A review, BioFactors, 45(1), 5-23 (2019).
S. Hall, S. Rudrawar, M. Zunk, N. Bernaitis, D. Arora, C.M. McDermott, S. Anoopkumar-Dukie, Protection against radiotherapy-induced toxicity, Antioxi-dants (Basel), 5(3), 22 (2016).
J. Chang, Y. Zhou, Q. Wang, M. Aschner, R. Lu, Plant components can reduce methylmercury toxication: A mini-review, Biochimica et Biophysica Acta (BBA)-General Subjects, 1863(12), 129290 (2019).
Cómo citar
APA
ACM
ACS
ABNT
Chicago
Harvard
IEEE
MLA
Turabian
Vancouver
Descargar cita
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.
Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13
